Jared Kaltwasser

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.

There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.

Two strategies were tried, but neither outperformed usual care.

Treatment resistance remains a major challenge in the treatment of acute myeloid leukemia (AML), and leveraging actionable therapeutic targets is far from straightforward.

The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate.

A retrospective analysis of Canadian cases finds clinicians turn to a variety of therapies for chronic graft-vs-host disease (GVHD) if corticosteroids fail.

Patients had a lower risk of their diffuse large B-cell lymphoma (DLBCL) progressing if they had consolidative radiotherapy, a new report shows.

Introducing ciprofloxacin to their institution’s empiric antimicrobial regimen for patients with AML and prolonged or recurrent neutropenic fevers appeared to reduce the risk of Bacillus cereus infection.

The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery.

Preventive measures can reduce the risk to newborns, but careful monitoring is necessary, the authors said.

A patient with chronic lymphocytic leukemia (CLL) who experience persistent exaggerated responses to insect bites was successfully treated with dupilumab.

The fully humanized monoclonal antibody led to results among patients with generalized myasthenia gravis (MG) similar to that of efgartigimod, the authors said.

The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma.

Investigators say the findings could lead to new therapeutic targets.

The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.

Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.

Other viral infections, including Epstein-Barr virus and hepatitis C, have already been linked with primary hepatic lymphoma, the authors said.

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).

The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.

These findings suggest complement protein levels may be an important biomarker for type 1 diabetes.

Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found.

The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing.

Investigators say adolescents had difficulty adhering to the workbook-based program, but the authors said changes—and perhaps a digital format—could improve the program’s performance.

A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.

Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.

About half of patients receiving the procedure did not need medication to control their blood pressure after 5 years.

The authors say their 3D model improves on results using traditional 2-dimensional approaches.

Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).